Latest 10-Q quarterly reports

Central Plains Bancshares, Inc. announced its first-quarter financial results, showcasing an increase in net income and a robust net interest margin.

Oaktree Acquisition Corp. III Life Sciences files its Q2 2026 10-Q, reporting net income driven by interest income and detailing its ongoing search for a business combination target.

Blueport Acquisition Ltd reports on its Q2 2026 financial status, highlighting progress on its merger agreement with SINGAUTO Inc. while acknowledging substantial doubt regarding its ability to continue as a going concern.

International Tower Hill Mines Ltd. reports substantial progress on its Livengood Gold Project, bolstered by a significant capital raise and advancements in feasibility studies.

ASPAC III Acquisition Corp. reports continued operational inactivity and significant challenges, including a potential Nasdaq delisting and substantial doubt regarding its going concern status, as it seeks a business combination.

Cartesian Growth Corporation IV has filed its quarterly report for the period ending June 30, 2026, detailing the successful completion of its Initial Public Offering and the significant capital raised.

Datacentrex, Inc. filed its Q2 2026 Form 10-Q, detailing a substantial net loss driven by increased operating expenses and digital asset market volatility, while revenues remained relatively stable.

Enovix Corporation reported a 21% increase in revenue for Q2 2026 compared to the prior year, driven by defense sector sales, but continued to experience significant operating losses and cash burn.

Alto Neuroscience reported a net loss of $27.6 million for Q2 2026, but bolstered its cash position with a $94.6 million offering and detailed progress across its seven clinical-stage assets.

ACP Holdings Acquisition Corp. reports on its financial condition and operational activities for the quarter ended June 30, 2026, detailing its IPO proceeds and ongoing search for a business combination.

QuickLogic Corporation's Q2 2026 Form 10-Q filing reveals a significant increase in revenue, driven by new product sales, though the company continues to report a net loss.

First Tracks Biotherapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, highlighting continued investment in R&D and progress in clinical trials, alongside a significant net loss.

First Community Corporation's Q2 2026 Form 10-Q filing reveals significant increases in net income and net interest income, bolstered by the acquisition of Signature Bank of Georgia and improved net interest margin.

Armata Pharmaceuticals, Inc. reported its second quarter 2026 financial results, highlighting progress in its phage therapy development programs while acknowledging substantial doubt regarding its ability to continue as a going concern.

United Acquisition Corp. I reports net income for Q2 2026 driven by interest on its trust account, while continuing its search for a business combination.

ERock, Inc. filed its Q2 2026 Form 10-Q, revealing a substantial decrease in total revenues driven by lower power system sales, alongside a significant increase in net loss and ongoing material weaknesses in internal controls.

Andersen Group Inc. announced a 23.7% year-over-year revenue increase for the first quarter of 2026, driven by organic growth and strategic international acquisitions.

InPoint Commercial Real Estate Income, Inc. reported a net loss for the second quarter of 2026, driven by credit loss provisions and property impairment, while also originating new loans and purchasing securities.

Lulus Fashion Lounge Holdings, Inc. has entered into a purchase agreement with ARC Group International Ltd. for up to $4.5 million in common stock to bolster working capital.

ArriVent BioPharma reported increased research and development expenses in Q2 2026, alongside a substantial cash and investment balance, as it advances its pipeline of novel therapeutics.

Research Alliance Corporation III (RACC) reports on its Q2 2026 financial status, highlighting progress towards its business combination with OHB Pediatrics Ltd. and maintaining a strong cash position.

Oncolytics Biotech reported increased operating expenses and a widening net loss for the six months ended June 30, 2026, while highlighting substantial doubt about its ability to continue as a going concern.

MIRA Pharmaceuticals, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing net losses, significant cash burn, and substantial doubt regarding its ability to continue as a going concern, alongside Nasdaq minimum bid price non-compliance.

Sunshine Silver Mining & Refining Company's Q2 2026 Form 10-Q reveals a substantial increase in net loss driven by higher pre-development and administrative expenses, despite significant cash infusion from its recent IPO.

Noble Roman's 10-Q filing for the period ending June 30, 2026, reveals a decrease in company-owned restaurant revenue and net income, while franchising revenue shows growth.

Allogene Therapeutics announced a leadership transition with Zachary Roberts appointed as President and CEO, effective July 1, 2026, while also providing updates on its ongoing clinical programs, including ALPHA3 and ALLO-316.

AEON Biopharma, Inc. reported continued operating losses and a significant accumulated deficit in its Q2 2026 10-Q filing, raising substantial doubt about its ability to continue as a going concern, even after recent capital raises.

ITG, Inc. announced its Q2 2026 financial results, showing a substantial increase in revenue driven by acquisitions, but a significant decline in net income and a net loss for the six-month period.

Jack in the Box reported a mixed third quarter for fiscal year 2026, with company restaurant sales showing a slight increase but same-store sales declining, alongside rising costs and a substantial net loss attributed to the prior sale of Del Taco.

Reeds Inc. filed its Q2 2026 10-Q, revealing a significant drop in net sales and a widening net loss, while facing substantial doubt regarding its going concern status.